ABUS - Arbutus Biopharma Corp

4.29
-0.160   -3.730%

Share volume: 1,372,965
Last Updated: 03-27-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.18%

PREVIOUS CLOSE
CHG
CHG%
$4.45
-0.16
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
38%
Profitability 35%
Dept financing 24%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.94%
1 Month
-8.14%
3 Months
-9.11%
6 Months
-3.81%
1 Year
22.57%
2 Year
66.28%
Key data
Stock price
$4.29
P/E Ratio 
N/A
DAY RANGE
$4.28 - $4.55
EPS 
-$0.17
52 WEEK RANGE
$2.70 - $5.10
52 WEEK CHANGE
$22.92
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
195.478 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-01-2025
BETA 
-0.51
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,705,230
AVERAGE 30 VOLUME 
$3,087,917
Company detail
CEO: William H. Collier
Region: US
Website: arbutusbio.com
Employees: 90
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Arbutus Biopharma Corporation develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate. AB-836, an oral capsid inhibitor that suppresses HBV DNA replication, is in Phase Ia/Ib clinical trial targeted to hepatocytes.

Recent news